Clovis Oncology (CLVS)宣佈，開始CO-1686（对付T790突变）臨床研究

小溪水草 · 发表于 2012-12-9 21:01:30

老马辛苦了。谢谢老马提供的前沿信息，我们有了新的希望。期待进一步的好消息！

yangyan8809 · 发表于 2012-12-10 11:23:55

老马辛苦，期待好消息。

格子妈 · 发表于 2012-12-10 12:07:32

等待，期望，热切地期望。

YUMI12 · 发表于 2012-12-10 14:10:22

等待，期待。。。。。希望。

站直了别趴下 · 发表于 2012-12-10 21:07:58

快点啊病人等不及的

爱妈妈 · 发表于 2012-12-10 21:38:01

希望能等到好希望

liangqj · 发表于 2012-12-11 08:49:18

可望不可及，几时能上市啊？

smallerme · 发表于 2012-12-11 23:44:12

辛苦老马了。前沿消息持续关注。

maidaomaidao · 发表于 2012-12-25 00:03:27

马哥总是给能给我们带来令人欣喜的好消息，大家把这个帖子顶起来！
在这祝马哥圣诞快乐！

老马 · 发表于 2013-2-23 15:44:55

本帖最后由老马于 2013-2-23 16:02 编辑

CO-1686与WZ4002结构类似，同属第三代EGFR抑制剂。
http://cancergrace.org/topic/afa ... -user-group/page/5/
MTD has not been reached in the CO-1686 trial. The dose started at 150 and I know someone on 900mg! The good news is there are virtually no side effects (some muscle pain?)。
--------------------------------------------------------------
CO-1686 – problem seems to be with its short half-life, so they’re now working on revising dosing schedules, as very high doses have been reached but it’s in and out of one’s body much too quickly. No side effects still, so that’s good，
-------------------------------------------------------------------------------------------------------------------------------------
The current dose cohorts (still in dose-escalation phase) are 1200mg once, twice, and three times a day (3 patients per dosing schedule).
There are currently 9 people on their waiting list (I’m #9), with new cohorts opening roughly every two months.
-------------------------------------------------------------------------------------------------------------------------------------------
Unfortunately, the Clovis trial has not reached MTD。